1. Recommendations for genetic testing to reduce the incidence of anthracycline‐induced cardiotoxicity
- Author
-
Bruce Carleton, Michael J. Rieder, Amit P. Bhavsar, Ursula Amstutz, Soomi Hwang, Karen A. Gelmon, Folefac Aminkeng, Anne Smith, Daniel Bernstein, Shahrad Rod Rassekh, Michael R. Hayden, Shubhayan Sanatani, and Colin J. D. Ross
- Subjects
medicine.medical_specialty ,Anthracycline ,cardiotoxicity ,Reviews ,Pharmacogenomic Testing ,030204 cardiovascular system & hematology ,Pharmacology ,anthracycline ,Lower risk ,03 medical and health sciences ,0302 clinical medicine ,Risk Factors ,medicine ,Humans ,cancer ,Anthracyclines ,Genetic Predisposition to Disease ,Pharmacology (medical) ,Genetic Testing ,guidelines ,610 Medicine & health ,Intensive care medicine ,Letter to the Editor ,Genetic testing ,pharmacogenomics ,Cardiotoxicity ,Evidence-Based Medicine ,medicine.diagnostic_test ,heart-failure ,business.industry ,Evidence-based medicine ,Multidrug Resistance-Associated Protein 2 ,Critical appraisal ,030220 oncology & carcinogenesis ,Pharmacogenomics ,business - Abstract
AIM Anthracycline-induced cardiotoxicity (ACT) occurs in 57% of treated patients and remains an important limitation of anthracycline-based chemotherapy. In various genetic association studies, potential genetic risk markers for ACT have been identified. Therefore, we developed evidence-based clinical practice recommendations for pharmacogenomic testing to further individualize therapy based on ACT risk. METHODS We followed a standard guideline development process; including a systematic literature search, evidence synthesis and critical appraisal, and the development of clinical practice recommendations with an international expert group. RESULTS RARG rs2229774, SLC28A3 rs7853758 and UGT1A6 rs17863783 variants currently have the strongest and the most consistent evidence for association with ACT. Genetic variants in ABCC1, ABCC2, ABCC5, ABCB1, ABCB4, CBR3, RAC2, NCF4, CYBA, GSTP1, CAT, SULT2B1, POR, HAS3, SLC22A7, SCL22A17, HFE and NOS3 have also been associated with ACT, but require additional validation. We recommend pharmacogenomic testing for the RARG rs2229774 (S427L), SLC28A3 rs7853758 (L461L) and UGT1A6*4 rs17863783 (V209V) variants in childhood cancer patients with an indication for doxorubicin or daunorubicin therapy (Level B - moderate). Based on an overall risk stratification, taking into account genetic and clinical risk factors, we recommend a number of management options including increased frequency of echocardiogram monitoring, follow-up, as well as therapeutic options within the current standard of clinical practice. CONCLUSIONS Existing evidence demonstrates that genetic factors have the potential to improve the discrimination between individuals at higher and lower risk of ACT. Genetic testing may therefore support both patient care decisions and evidence development for an improved prevention of ACT.
- Published
- 2016
- Full Text
- View/download PDF